Business
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality careNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $1
About this update from Lifemd, Inc.
[{"type":"image","alt":"LifeMD, Inc.","displaySize":"","headline":null,"caption":"LifeMD, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/61gLXi5OwzzXYAEyNdYSZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc","width":300,"height":300}},"lazy":false},{"type":"text","content":"LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care","length":149,"tagName":"p"},{"type":"text","content":"NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $199 per month—the lowest cash-pay pricing available nationwide—for two fills for new patients. The offering is designed to support patients who pay out of pocket.","length":512,"tagName":"p"},{"type":"text","content":"These medications are available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD’s dedicated clinical team, access to diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes that are important for sustained weight loss and metabolic health.","length":394,"tagName":"p"},{"type":"text","content":"This update follows recent national efforts to improve affordability and access to GLP-1 therapies, including initiatives led by the White House and leading pharmaceutical manufacturers such as Novo Nordisk and Eli Lilly. As these developments continue to shape the market, LifeMD’s infrastructure, partnerships, and virtual care model position the company as a key player in supporting patients seeking clinically guided weight-loss care.","length":439,"tagName":"p"},{"type":"text","content":""We are proud to continue offering the most competitive cash-pay pricing for GLP-1 therapies in America," said Justin Schreibe...